RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases
- 30 March 2012
- journal article
- Published by Springer Science and Business Media LLC in Clinical & Experimental Metastasis
- Vol. 29 (6), 551-559
- https://doi.org/10.1007/s10585-012-9470-8
Abstract
Raf kinase inhibitor protein (RKIP) is an inhibitor of Raf-mediated activation of mitogen-activated protein (MAP) kinase (MEK)-MAP kinase and is considered as an important tumor suppressor. RKIP-expression was investigated retrospectively in 321 esophageal cancers [179 adenocarcinomas (ACs), 142 squamous cell carcinomas (SCCs)]. RKIP-expression was further investigated in 41 precursor lesions consisting of 14 cases of non-dysplastic Barrett’s mucosa, 5 low grade dysplasias (LGD), and 12 high grade dysplasias (HGD) as well as, 4 cases with low grade and 6 cases with high-grade squamous cell dysplasia. Corresponding lymph node metastases were investigated in 140 patients, distant metastases in 29, and local recurrences in 12. High RKIP-expression was significantly more common in Barrett’s mucosa without dysplasia and in LGD compared to HGD (p = 0.047, χ2 test) and invasive AC (p < 0.001, χ2 test). In 187 primary esophageal cancers (58.3 %) RKIP was downregulated (AC: 51.4 %; SCC: 66.9 %). RKIP status of primary tumors influenced RKIP expression in corresponding lymph node and distant metastases (p < 0.05, linear regression). Downregulation of RKIP was associated with shorter overall survival (OS) and disease free survival (DFS) in all tumors (p ≤ 0.05, Cox regression). In AC, downregulation of RKIP was an independent prognostic factor for OS and DFS (p ≤ 0.05, Cox regression), while in SCC it reached significance only in univariate analysis (p ≤ 0.05, log-rank test). In conclusion, downregulation of RKIP is associated with shorter survival in esophageal cancers, and RKIP status of tumor cells seems to be preserved at the formation of metastases. Inhibition of RKIP-downregulation might reduce the ability of esophageal cancers to establish disseminated disease.Keywords
This publication has 25 references indexed in Scilit:
- Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expressionCancer Letters, 2010
- Esophagogastric cancer: Targeted agentsCancer Treatment Reviews, 2010
- Two-marker protein profile predicts poor prognosis in patients with early rectal cancerBritish Journal of Cancer, 2008
- Expression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinomaBritish Journal of Cancer, 2008
- Loss of Raf Kinase Inhibitory Protein Induces Radioresistance in Prostate CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Effects of Raf Kinase Inhibitor Protein Expression on Metastasis and Progression of Human Epithelial Ovarian CancerMolecular Cancer Research, 2008
- Expression of Carbonic Anhydrase IX (CA IX), a Hypoxia-Related Protein, Rather Than Vascular-Endothelial Growth Factor (VEGF), a Pro-Angiogenic Factor, Correlates With an Extremely Poor Prognosis in Esophageal and Gastric AdenocarcinomasAnnals of Surgery, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Raf Kinase Inhibitor Protein Interacts with NF-κB-Inducing Kinase and TAK1 and Inhibits NF-κB ActivationMolecular and Cellular Biology, 2001
- The Role of DNA Methylation in Mammalian EpigeneticsScience, 2001